Judith Betts
Nephrology · Austin, TXNPI 1992735120
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,673 and has fallen 84.8% since, to $254 in 2025.
Across 175 payments — averaging $35.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- AstraZeneca$917
- Amgen$891
- Vifor Pharma, Inc.$747
- Aurinia Pharma U.S., Inc.$713
- Otsuka America Pharmaceutical, Inc.$409
- plus $2K from 14 others
Across 370 payments — averaging $10,007 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1.7M
- AstraZeneca$904K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$368K
- Akebia Therapeutics Inc$270K
- Astrazeneca UK Limited$220K
- GSK$146K
- plus $105K from 5 others
What the payments were for
- Speaking & faculty fees$2003%
- Food & beverage$6,08297%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 28 | $1,111 |
| AstraZeneca(2 entities) | 30 | $917 |
| Amgen(2 entities) | 20 | $891 |
| Vifor Pharma, Inc. | 14 | $747 |
| Aurinia Pharma U.S., Inc. | 14 | $713 |
| Otsuka America Pharmaceutical, Inc. | 22 | $409 |
| Novo Nordisk | 4 | $360 |
| Mallinckrodt Hospital Products Inc. | 7 | $274 |
| GSK | 6 | $170 |
| Daiichi Sankyo Inc. | 8 | $153 |
| Calliditas Therapeutics US Inc. | 1 | $139 |
| OPKO Pharmaceuticals, LLC | 7 | $107 |
| Fresenius USA Marketing, Inc. | 4 | $72 |
| Boehringer Ingelheim | 2 | $50 |
| Akebia Therapeutics Inc | 2 | $43 |
| Mallinckrodt Enterprises LLC | 2 | $38 |
| Novartis | 1 | $32 |
| Travere Therapeutics, Inc. | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Outset Medical Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,288 in reported general payments places this provider in the 80th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Austin
- Harry GossAustin$159K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.